The endogenous role of hindbrain ghrelin receptors in regulating feeding behavior
In this project, I investigated the endogenous role of hindbrain ghrelin receptors in regulating feeding behavior. In order to test our hypothesis that the hindbrain ghrelin receptor, growth hormone secretagogue receptor 1a (GHSR1a), plays a physiological role in the hindbrain to increase food intake we [1] chronically knocked down GHSR1a in the NTS using an AAV shRNA and [2] acutely injected the endogenous GHSR1a antagonist LEAP-2 into the fourth (hindbrain) ventricle. Throughout the course of the experiment, we measured chow intake and body weight after injecting either ghrelin or CCK to determined whether chow intake was increased or decreased. We also measured baseline chow intake and body weight before the experiment ran, and light versus dark cycle intake to determine if the knock down virus affected when the rat subjects consumed their food. In addition, we conducted a follow up experiment involving LEAP-2, the endogenous GHSR1a antagonist. We injected varying amounts of LEAP-2 and subsequently measured chow intake and body weight. The goal of the project was to determine how the chronic NTS knock down of GHSR1a affected chow intake and body weight in different scenarios and determine how hindbrain injection of LEAP-2 affected chow intake and body weight.
Comments
Interesting Difference between GHSR1a KD vs LEAP-2 Injection
Reading through your presentation, I found it quite interesting that a KD of the GHSR1a was only able to attenuate ghrelin stimulated chow intake. This fact further surprised me when you showed that acute LEAP-2 injections decrease chow intake and body weight. Since LEAP-2 is an antagonist of GHSR1a, I expected to see similar results between it and the KD of GHSR1a. I hope that more research will be done to fully understand the role of GHSR1a in food intake and the magnitude of its antagonism by LEAP-2.
Interesting Difference between GHSR1a KD vs LEAP-2 Injection
Reading through your presentation, I found it quite interesting that a KD of the GHSR1a was only able to attenuate ghrelin stimulated chow intake. This fact further surprised me when you showed that acute LEAP-2 injections decrease chow intake and body weight. Since LEAP-2 is an antagonist of GHSR1a, I expected to see similar results between it and the KD of GHSR1a. I hope that more research will be done to fully understand the role of GHSR1a in food intake and the magnitude of its antagonism by LEAP-2.
Great Job!
Hi Matti!
You did a great job on your poster. I thought it was very interesting that the NTS knockdown of the GHSR1a did not result in baseline differences in chow intake or body weight. I wonder why this is the case and look forward to learning more.